Safety and Efficacy of TRC4186 in the treatment of stable heart failure associated with HbA1C 6.0% or type 2 Diabetes receiving oral hypoglycaemic therapy (with or without additional insulin) as an add-on to conventional treatment for heart failure.

Trial Profile

Safety and Efficacy of TRC4186 in the treatment of stable heart failure associated with HbA1C 6.0% or type 2 Diabetes receiving oral hypoglycaemic therapy (with or without additional insulin) as an add-on to conventional treatment for heart failure.

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs TRC 4186 (Primary)
  • Indications Chronic heart failure; Diabetes mellitus; Diabetic complications
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 11 Apr 2012 Status changed from recruiting to completed as reported by Clinical Trials Registry - India record.
    • 26 Jun 2010 Planned number of patients changed from 230 to 300 as reported by Clinical Trials Registry - India.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top